{"nctId":"NCT02462122","briefTitle":"Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis","startDateStruct":{"date":"2015-08-19","type":"ACTUAL"},"conditions":["Plaque Psoriasis"],"count":215,"armGroups":[{"label":"IDP-118 Lotion","type":"EXPERIMENTAL","interventionNames":["Drug: IDP-118 Lotion"]},{"label":"IDP-118 Vehicle Lotion","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: IDP-118 Vehicle Lotion"]}],"interventions":[{"name":"IDP-118 Lotion","otherNames":["Lotion"]},{"name":"IDP-118 Vehicle Lotion","otherNames":["Vehicle"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Male or female, of any race, at least 18 years of age (inclusive).\n* Freely provides both verbal and written informed consent.\n* Has an area of plaque psoriasis appropriate for topical treatment that covers a BSA of at least 3%, but no more than 12%. The face, scalp, palms, soles, axillae and intertriginous areas are to be excluded in this calculation.\n* Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural and artificial) for the duration of the study.\n* Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or 4. (The face, scalp, palms, soles, axillae and intertriginous areas are to be excluded in this assessment).\n\nKey Exclusion Criteria:\n\n* Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined by the investigator.\n* Presents with psoriasis that was treated with prescription medication and failed to respond to treatment, even partially or temporarily, as determined by the investigator.\n* Presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, as determined by the investigator.\n* Is pregnant, nursing an infant, or planning a pregnancy during the study period.\n* Has received treatment with any investigational drug or device within 60 days or 5 drug half lives (whichever is longer) prior to the Baseline visit, or is concurrently participating in another clinical study with an investigational drug or device.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Participants With Treatment Success at Week 8","description":"Treatment success was defined as at least a 2-grade improvement from Baseline in IGA score and an IGA score equating to \"Clear\" or \"Almost Clear\". IGA was based on a 5-point scale ranging from 0 to 4; where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.33","spread":null},{"groupId":"OG001","value":"12.51","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Treatment Success at Weeks 12, 6, 4, and 2","description":"Treatment success was defined as at least a 2-grade improvement from Baseline in IGA score and an IGA score equating to \"Clear\" or \"Almost Clear\". IGA was based on a 5-point scale ranging from 0 to 4; where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.35","spread":null},{"groupId":"OG001","value":"8.84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.53","spread":null},{"groupId":"OG001","value":"8.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.96","spread":null},{"groupId":"OG001","value":"1.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.77","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":137},"commonTop":["Dermatitis contact","Pruritis"]}}}